Trial reportHaematologica2019
Clinical and molecular characteristics of
Open access · goldAbstract readClinical TrialMulticenter Study
In one paragraph
Trial report in Haematologica, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers.
0numbers the graph read from it
0cells of the map it votes in
53citing papers in PubMed
10.1field-weighted citation impact, top 2% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
53 citing papers in PubMed, 92 citations in OpenAlex.
- Trial
- Fusion gene map of acute leukemia revealed by transcriptome sequencing of a consecutive cohort of 1000 cases in a single center.Blood cancer journal · 2021Trial
- How do low-complexity domain interactions control transcription?Biochemical Society transactions · 2026Review
- The Diverse Roles of the MEF2 Transcription Factor Family in Tumor Progression and Emerging Therapeutic Opportunities.Biomedicines · 2026Review
- Hsa_circ_0013729 Promotes Gastric Cancer Progression by Regulating MEF2D in ceRNA- and RBP- Dependent Manners.Biochemical genetics · 2026Article
- TCF3::HLF orchestrates an enhancer-promoter network with activation of MEF2C to promote immature HSC gene expression in leukemia.Science advances · 2026Article
- The clinical characteristics and prognosis analysis of acute B-cell lymphoblastic leukemia with MEF2D fusions.Annals of hematology · 2026Article
- Distribution of molecular subtypes in a Colombian cohort of patients with acute lymphoblastic leukemia using whole-transcriptome analysis.Frontiers in oncology · 2026Article
- A Decade of Transformation in the Management of Childhood Acute Lymphoblastic Leukemia: From Conventional Chemotherapy to Precision Medicine.Pediatric reports · 2025Review
- Role of human Myocyte Enhancer Factor 2 (MEF2) proteins in cancer: structural insights, functional diversity, and regulatory mechanisms.Cancer cell international · 2025Review
- Molecular mechanisms of unique therapeutic potential of CUDC-907 for MEF2D fusion-driven BCP-ALL.Signal transduction and targeted therapy · 2025Article
- Review
- Genetics of B-Cell Acute Lymphoblastic Leukemia (B-ALL): Recent Updates and Indian Perspective.Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion · 2025Review
- CD5-positive B-cell acute lymphoblastic leukemia/lymphoma with MEF2D::BCL9 mimicking aggressive mature B-cell lymphoma: a case report of a newly described entity and potential diagnostic pitfall.Journal of hematopathology · 2025Article
- CD36 cell surface expression as a surrogate marker to identify ABL/JAK-class kinase fusions in pediatric BCP-ALL.Leukemia · 2025Article
- Unraveling the Genetic Heterogeneity of Acute Lymphoblastic Leukemia Based on NGS Applications.Cancers · 2024Review
- Genetic and clinical characteristics of acute B-cell lymphoblastic leukemia with MEF2D fusions and report of two novel MEF2D rearrangements.Annals of hematology · 2024Article
- Identification of a novel MEF2C::SS18L1 fusion in childhood acute B-lymphoblastic leukemia.Journal of cancer research and clinical oncology · 2024Article
- Acute lymphoblastic leukaemia.Nature reviews. Disease primers · 2024Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
39 authors at 20 institutions in 2 countries.
Kentaro OhkiDepartment of Pediatric Hematology and Oncology Research, National Research Institute for Child Health and Development, Setagaya-ku, Tokyo oki-kn@ncchd.go.jp.
Nobutaka KiyokawaDepartment of Pediatric Hematology and Oncology Research, National Research Institute for Child Health and Development, Setagaya-ku, Tokyo.
Yuya SaitoDepartment of Pediatric Hematology and Oncology Research, National Research Institute for Child Health and Development, Setagaya-ku, Tokyo.
Shinsuke HirabayashiDepartment of Pediatric Hematology and Oncology Research, National Research Institute for Child Health and Development, Setagaya-ku, Tokyo.
Kazuhiko NakabayashiDepartment of Maternal-Fetal Biology, National Research Institute for Child Health and Development, Setagaya-ku, Tokyo.
Hitoshi IchikawaFundamental Innovative Oncology Core, National Cancer Center Research Institute, Chuo-ku, Tokyo.
Yukihide MomozawaLaboratory for Genotyping Development, RIKEN Center for Integrative Medical Sciences (IMS), Yokohama-shi, Kanagawa.
Kohji OkamuraDepartment of Systems BioMedicine, National Research Institute for Child Health and Development, Setagaya-ku, Tokyo.
Ai YoshimiDepartment of Pediatric Hematology and Oncology Research, National Research Institute for Child Health and Development, Setagaya-ku, Tokyo.
Hiroko Ogata-KawataDepartment of Maternal-Fetal Biology, National Research Institute for Child Health and Development, Setagaya-ku, Tokyo.
Hiromi SakamotoFundamental Innovative Oncology Core, National Cancer Center Research Institute, Chuo-ku, Tokyo.
Motohiro KatoDepartment of Pediatric Hematology and Oncology Research, National Research Institute for Child Health and Development, Setagaya-ku, Tokyo.
Keitaro FukushimaDepartment of Pediatrics, Dokkyo Medical University, Tochigi.
Daisuke HasegawaDepartment of Pediatrics, St. Luke's International Hospital, Chuo-ku, Tokyo.
Hiroko FukushimaDepartment of Pediatrics, University of Tsukuba Hospital, Ibaraki.
Masako ImaiDepartment of Pediatrics, Japanese Red Cross Musashino Hospital, Tokyo.
Ryosuke KajiwaraDepartment of Pediatrics, Yokohama City University Hospital, Kanagawa.
Takashi KoikeDepartment of Pediatrics, Tokai University School of Medicine, Kanagawa.
Isao KomoriDepartment of Pediatrics, Matsudo City Hospital, Chiba.
Atsushi MatsuiDepartment of Pediatrics, Japanese Red Cross Maebashi Hospital, Gunma.
Makiko MoriDepartment of Hematology/Oncology, Saitama Children's Medical Center.
Koichi MoriwakiDepartment of Pediatrics, Saitama Medical Center, Saitama Medical University.
Yasushi NoguchiDepartment of Pediatrics, Japanese Red Cross Narita Hospital, Chiba.
Myoung-Ja ParkDepartment of Hematology/Oncology, Gunma Children's Medical Center, Shibukawa-shi.
Takahiro UedaDepartment of Pediatrics, Nippon Medical School, Bunkyo-ku, Tokyo.
Shohei YamamotoDepartment of Pediatrics, Showa University Fujigaoka Hospital, Yokohama-shi, Kanagawa.
Koichi MatsudaLaboratory of Clinical Genome Sequencing Department of Computational Biology and Medical Sciences Graduate School of Frontier Sciences, The University of Tokyo, Minato-ku.
Teruhiko YoshidaFundamental Innovative Oncology Core, National Cancer Center Research Institute, Chuo-ku, Tokyo.
Kenji MatsumotoDepartment of Allergy and Clinical Immunology, National Research Institute for Child Health and Development, Setagaya-ku, Tokyo.
Kenichiro HataDepartment of Maternal-Fetal Biology, National Research Institute for Child Health and Development, Setagaya-ku, Tokyo.
Michiaki KuboLaboratory for Genotyping Development, RIKEN Center for Integrative Medical Sciences (IMS), Yokohama-shi, Kanagawa.
Yoichi MatsubaraDirector, National Research Institute for Child Health and Development, Setagaya-ku, Tokyo.
Hiroyuki TakahashiDepartment of Pediatrics, Toho University Omori Medical Center, Tokyo.
Takashi FukushimaDepartment of Child Health, Faculty of Medicine, University of Tsukuba, Ibaraki.
Yasuhide HayashiInstitute of Physiology and Medicine, Jobu University, Takasaki-shi, Gunma, Japan.
Katsuyoshi KohDepartment of Hematology/Oncology, Saitama Children's Medical Center.
Atsushi ManabeDepartment of Pediatrics, St. Luke's International Hospital, Chuo-ku, Tokyo.
Akira OharaDepartment of Pediatrics, Toho University Omori Medical Center, Tokyo.
Tokyo Children’s Cancer Study Group (TCCSG)
National Center For Child Health and Development · JPNational Cancer Research Institute · GBRIKEN Center for Integrative Medical Sciences · JPSaitama Children's Medical Center · JPSt. Luke's International Hospital · JPDokkyo Medical University · JPGunma Children's Medical Center · JPJapanese Red Cross Narita Hospital · JPJobu University · JPMaebashi Red Cross Hospital · JPMatsudo City Hospital · JPMusashino Red Cross Hospital · JPNippon Medical School · JPShowa University Fujigaoka Hospital · JPSocial Insurance Saitama Chuo Hospital · JPThe University of Tokyo · JPToho University · JPToho University Omori Medical Center · JPTokai University · JPTokyo Metropolitan Children's Medical Center · JP
Funding
No grant is acknowledged in the PubMed record.
Abstract
Fusion genes involving
Indexed as
Heterogeneous-Nuclear RibonucleoproteinsOncogene Proteins, FusionPrecursor B-Cell Lymphoblastic Leukemia-LymphomaTranslocation, GeneticAdolescentChildDisease-Free SurvivalFemaleHumansMaleMEF2 Transcription FactorsSurvival RateHeterogeneous-Nuclear RibonucleoproteinsMEF2D protein, humanMEF2 Transcription FactorsOncogene Proteins, Fusion
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.